However, the potential of these metabolites to act as molecular glues between PDE3A and SLFN12 remains unexplored, despite the fact that ANA drug sensitivity in tumor cells is thought to mostly correlate with these protein expression levels (Nazir et al., 2017; An et al., 2019). This evidence concerns the gene SLFN12 and neoplasm.